Docosahexaenoic acid (DHA) sensitizes Brain tumor cells to etoposide-induced apoptosis

Current Molecular Medicine

Volumn 11, Issue 6, 2011, Pages 503-511

  Wang, F ^a   Bhat, K ^a   Doucette, M ^a   Zhou, S ^a   Gu, Y ^a   Law, B ^a   Liu, X ^b   Wong, E T ^c   Kang, J X ^d   Hsieh, T C ^e   Qian, S Y ^a   Wu, E ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Docosahexaenoic acid; Etoposide; Glioblastoma; Medulloblastoma

Indexed keywords

BCL2 PROTEIN; DOCOSAHEXAENOIC ACID; ETOPOSIDE; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAT1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 14; NUCLEAR FACTOR KAPPA BIA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA REPAIR; DOWN REGULATION; DRUG MECHANISM; GENE REPRESSION; GENOTYPE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; MOLECULAR MIMICRY; MONOTHERAPY; SIGNAL TRANSDUCTION; STAINING; TUMOR CELL;

EID: 79960338573     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411796268740     Document Type: Article

References (49)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
2. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010; 9: 135.
3. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010; 10(5): 319-31.
4. Lukiw WJ, Bazan NG. Docosahexaenoic acid and the aging brain. J Nutr 2008; 138(12): 2510-4.
5. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 2009; 77(6): 937-46.
6. Ferguson LR, Philpott M. Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Targets 2007; 7(5): 459-64.
7. Hardman WE. Dietary canola oil suppressed growth of implanted MDA-MB 231 human breast tumors in nude mice. Nutr Cancer 2007; 57(2): 177-83.
8. Chamras H, Ardashian A, Heber D, Glaspy JA. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem 2002; 13(12): 711-6.
9. Mandal CC, Ghosh-Choudhury T, Yoneda T, Choudhury GG, Ghosh-Choudhury N. Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res Commun 2010; 402(4): 602-7.
10. Vibet S, Goupille C, Bougnoux P, Steghens JP, Gore J, Maheo K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 2008; 44(7): 1483-91.
11. Maheo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, Bougnoux P, et al. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 2005; 39(6): 742-51.
12. Menendez JA, Lupu R, Colomer R. Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 2005; 14(3): 263-70.
13. Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol 2005; 55(1): 12-20.
14. Narayanan NK, Narayanan BA, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol 2005; 26(3): 785-92.
15. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004; 3(2): 215-21.
16. Toit-Kohn JL, Louw L, Engelbrecht AM. Docosahexaenoic acid induces apoptosis in colorectal carcinoma cells by modulating the PI3 kinase and p38 MAPK pathways. J Nutr Biochem 2009; 20(2): 106-14.
17. Wu H, Ichikawa S, Tani C, et al. Docosahexaenoic acid induces ERK1/2 activation and neuritogenesis via intracellular reactive oxygen species production in human neuroblastoma SH-SY5Y cells. Biochim Biophys Acta 2009; 1791(1): 8-16.
18. Zhuo Z, Zhang L, Mu Q, et al. The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev Biol Anim 2009; 45(1-2): 69-74.
19. Shaikh IA, Brown I, Schofield AC, Wahle KW, Heys SD. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway. Prostate 2008; 68(15): 1635-46.
20. Narayanan NK, Narayanan BA, Bosland M, Condon MS, Nargi D. Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer 2006; 119(7): 1586-98.
21. Kato T, Kolenic N, Pardini RS. Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr Cancer 2007; 58(2): 178-87.
22. Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol 2009; 27(4): 566-71.
23. Saylors RL, Sidransky D, Friedman HS, et al. Infrequent p53 gene mutations in medulloblastomas. Cancer Res 1991; 51(17): 4721-3.
24. Vogelbaum MA, Tong JX, Perugu R, Gutmann DH, Rich KM. Overexpression of bax in human glioma cell lines. J Neurosurg 1999; 91(3): 483-9.
25. Tian Z, Palmer N, Schmid P, et al. A practical platform for blood biomarker study by using global gene expression profiling of peripheral whole blood. PLoS One 2009; 4(4): e5157.
26. Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008; 3(11): e3794.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9): e45.
28. Zhang H, Bajraszewski N, Wu E, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117(3): 730-8.
29. Callen E, Jankovic M, Wong N, Zha S, Chen HT, Difilippantonio S, et al. Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Mol Cell 2009; 34(3): 285-97.
30. Harada N, Mizoi T, Kinouchi M, et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 2001; 91(1): 67-75.
31. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004; 35(3): 211-31.
32. Wang HS, Hung Y, Su CH, et al. CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1). Exp Cell Res 2005; 304(1): 116-26.
33. Miletti-Gonzalez KE, Chen S, Muthukumaran N, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005; 65(15): 6660-7.
34. Subramaniam V, Vincent IR, Gardner H, Chan E, Dhamko H, Jothy S. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 2007; 83(2): 207-15.
35. Wang SJ, Wreesmann VB, Bourguignon LY. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer. Head Neck 2007; 29(6): 550-8.
36. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003; 35(3): 197-8.
37. Gilbertson RJ, Langdon JA, Hollander A, et al. Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 2006; 42(5): 646-9.
38. Yuan L, Santi M, Rushing EJ, Cornelison R, MacDonald TJ. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clin Exp Metastasis 2010; 27(7): 481-91.
39. Abouantoun TJ, Macdonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 2009; 8(5): 1137-47.
40. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29(2): 143-52.
41. Wang FMAP, Doucette M, Bhat K, Li X, Law S, Kohane S, Wu E. PDGFR alpha and PDGFR beta differentially regulate cell proliferation and migration/invasion in medulloblastoma cells. 101st AACR Annual Meeting 2010 April 17-21.
42. Peddi P, Loftin CW, Dickey JS, et al. DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. Free Radic Biol Med 2010; 48(10): 1435-43.
43. Chen GG, Sin FL, Leung BC, Ng HK, Poon WS. Glioblastoma cells deficient in DNA-dependent protein kinase are resistant to cell death. J Cell Physiol 2005; 203(1): 127-32.
44. Chen GG, Sin FL, Leung BC, Ng HK, Poon WS. Differential role of hydrogen peroxide and staurosporine in induction of cell death in glioblastoma cells lacking DNA-dependent protein kinase. Apoptosis 2005; 10(1): 185-92.
45. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88(2): 386-401.
46. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key olecular signaling pathways and therapy targets. Acta Oncol 2009; 48(6): 811-21.
47. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7(12): 979-87.
48. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14(16): 5000-5.
49. Wiranowska M, Ladd S, Smith SR, Gottschall PE. CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biol 2006; 35(2-3): 159-72.